Literature DB >> 8842438

Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects.

H Tenor1, A Hatzelmann, M K Church, C Schudt, J K Shute.   

Abstract

1. The effects of the non-selective phosphodiesterase (PDE) inhibitor theophylline and the selective PDE4 inhibitor rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of complement 5a (C5a)- and platelet-activating factor (PAF)-stimulated human eosinophils obtained from normal and atopic donors were investigated. 2. Eosinophils were purified from peripheral venous blood of normal and atopic subjects by an immunomagnetic procedure to a purity > 99%. Eosinophils were stimulated with PAF (0.1 microM) or C5a 0.1 microM for 15 min and LTC4 was measured by radioimmunoassay (RIA). Eosinophil chemotaxis in response to PAF and C5a was assessed with 48-well microchambers (Boyden). 3. Under these conditions substantial amounts of LTC4 (about 300-1000 pg per 10(6) cells) were only detectable in the presence of indomethacin (0.1-10 microM). To explain this finding it was hypothesized that indomethacin reversed the inhibition of LTC4 synthesis by endogenously synthesized prostaglandins, in particular prostaglandin E2 (PGE2). In fact, eosinophils release 23 pg PGE2 per 10(6) cells following PAF stimulation; this PGE2 synthesis was completely inhibited by indomethacin and readdition of PGE2 inhibited eosinophil LTC4 synthesis (IC50 = 3 nM). The following experiments were performed in the presence of 10 microM indomethacin. 4. Theophylline (IC50 approximately 50 microM) and rolipram (IC50 approximately 0.03-0.2 microM) suppressed PAF- and C5a-stimulated LTC4 synthesis. This PDE inhibitor-induced suppression of LTC4 generation is mediated by activation of protein kinase A, since it was reversed by the protein kinase A inhibitor Rp-8-Br-cyclic AMPS. In addition, exogenous arachidonic acid concentration-dependently (0.3 microM-3 microM) reversed the inhibition of LTC4 synthesis by the PDE inhibitors, indicating that theophylline and rolipram suppress the mobilization of arachidonic acid. The beta 2-adrenoceptor agonist salbutamol inhibited eosinophil LTC4 synthesis (IC50 = 0.08 microM). The combination of salbutamol with theophylline (10 microM) or rolipram (3 nM) appeared to be additive. 5. Theophylline (IC50 approximately 40 microM), rolipram (IC50 approximately 0.02 microM [C5a], approximately 0.6 microM [PAF]) and PGE2 (IC50 approximately 3 nM) inhibited C5a- and PAF-stimulated eosinophil chemotaxis. The combination of PGE2 with theophylline resulted in an additive effect. 6. Both C5a- and PAF-stimulated eosinophil chemotaxis and LTC4 generation were significantly elevated in eosinophils from atopic individuals compared to normal subjects. However, eosinophils from normal and atopic individuals were not different with respect to their total cyclic AMP-PDE and PDE4 isoenzyme activities as well as the potencies of theophylline and rolipram to suppress LTC4 generation and chemotaxis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8842438      PMCID: PMC1909817          DOI: 10.1111/j.1476-5381.1996.tb15598.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

Review 1.  Recent progress in understanding the hormonal regulation of phosphodiesterases.

Authors:  M Conti; G Nemoz; C Sette; E Vicini
Journal:  Endocr Rev       Date:  1995-06       Impact factor: 19.871

2.  Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.

Authors:  G Dent; M A Giembycz; P M Evans; K F Rabe; P J Barnes
Journal:  J Pharmacol Exp Ther       Date:  1994-12       Impact factor: 4.030

3.  Contraction of human bronchial smooth muscle caused by activated human eosinophils.

Authors:  K F Rabe; N M Muñoz; A J Vita; B E Morton; H Magnussen; A R Leff
Journal:  Am J Physiol       Date:  1994-09

4.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy.

Authors:  J Kidney; M Dominguez; P M Taylor; M Rose; K F Chung; P J Barnes
Journal:  Am J Respir Crit Care Med       Date:  1995-06       Impact factor: 21.405

Review 5.  PDE isoenzymes as targets for anti-asthma drugs.

Authors:  C Schudt; H Tenor; A Hatzelmann
Journal:  Eur Respir J       Date:  1995-07       Impact factor: 16.671

6.  Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils.

Authors:  T Kaneko; R Alvarez; I F Ueki; J A Nadel
Journal:  Cell Signal       Date:  1995-07       Impact factor: 4.315

7.  The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results.

Authors:  R Djukanović; J P Finnerty; C Lee; S Wilson; J Madden; S T Holgate
Journal:  Eur Respir J       Date:  1995-05       Impact factor: 16.671

8.  Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.

Authors:  A Hatzelmann; H Tenor; C Schudt
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

9.  Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs.

Authors:  K H Banner; C P Page
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

Review 10.  Cyclic nucleotides and phosphodiesterases and airway function.

Authors:  P J Barnes
Journal:  Eur Respir J       Date:  1995-03       Impact factor: 16.671

View more
  13 in total

1.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma.

Authors:  A S Cowburn; K Sladek; J Soja; L Adamek; E Nizankowska; A Szczeklik; B K Lam; J F Penrose; F K Austen; S T Holgate; A P Sampson
Journal:  J Clin Invest       Date:  1998-02-15       Impact factor: 14.808

Review 2.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

Review 3.  Roles of roflumilast, a selective phosphodiesterase 4 inhibitor, in airway diseases.

Authors:  Theerasuk Kawamatawong
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 4.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

5.  A Nonhuman Primate PET Study: Measurement of Brain PDE4 Occupancy by Roflumilast Using (R)-[11C]Rolipram.

Authors:  Akihiro Takano; Tolga Uz; Jesus Garcia-Segovia; Max Tsai; Gezim Lahu; Nahid Amini; Ryuji Nakao; Zhisheng Jia; Christer Halldin
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  Effects of non-steroidal anti-inflammatory drugs on cyclo-oxygenase and lipoxygenase activity in whole blood from aspirin-sensitive asthmatics vs healthy donors.

Authors:  P A Gray; T D Warner; I Vojnovic; P Del Soldato; A Parikh; G K Scadding; J A Mitchell
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

7.  Effect of cilomilast (Ariflo) on TNF-alpha, IL-8, and GM-CSF release by airway cells of patients with COPD.

Authors:  M Profita; G Chiappara; F Mirabella; R Di Giorgi; L Chimenti; G Costanzo; L Riccobono; V Bellia; J Bousquet; A M Vignola
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 8.  Novel methylxanthine derivative-mediated anti-inflammatory effects in inflammatory bowel disease.

Authors:  In-Ah Lee; Alan Kamba; Daren Low; Emiko Mizoguchi
Journal:  World J Gastroenterol       Date:  2014-02-07       Impact factor: 5.742

Review 9.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Evaluation of PDE4 inhibition for COPD.

Authors:  Desuo Wang; Xiangli Cui
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.